The earnings call highlighted significant progress in cost reduction, revenue increase, and new product sales, alongside promising clinical study results. There was also strong progress in licensing and partnerships. However, concerns about uncertain revenue projections and decreasing cash reserves were noted.

Company Guidance -

Q3 2025

During VolitionRx Limited's Second Quarter 2025 Earnings Conference Call, the company provided updates on several key financial and operational metrics. The total operating expenses for Q2 2025 declined by 9% compared to the same period in 2024, primarily due to reduced personnel and R&D costs. Consequently, net cash used in operating activities decreased to $6.3 million from $6.7 million year-over-year. For the first half of 2025, net cash used in operations totaled $10.6 million, marking a 30% reduction from the prior year. Revenue for the quarter exceeded $400,000, contributing to a first-half total of over $650,000, reflecting a 15% increase. The company reported its first revenue from Nu.Q NETs human product sales, marking a significant milestone. Cash and cash equivalents at the end of the quarter stood at approximately $2.3 million, down from $3.3 million at the end of 2024. Additionally, the company received $6 million from a convertible loan note during the quarter and $1.2 million from a registered direct offering afterward.

Significant Reduction in Operating Costs

Total operating expenses for Q2 declined by 9% compared to Q2 2024, with a 22% reduction in total operating costs for the first half of 2025.

Increased Revenue and First Human Product Sales

Revenue increased by 15% in the first half of 2025, and the company recorded its first revenue from sales of the human product, Nu.Q NETs.

Promising Clinical Study Results

Interim analysis of 832 patients showed Nu.Q H3K27 trimethyl as a strong prognostic marker in non-small cell lung cancer.

Strong Licensing and Partnership Progress

Confidential discussions with over 10 companies with a combined market value exceeding $600 billion, aiming to secure multiple licensing agreements.

Expansion of Nu.Q Vet Product

FujiFilm Vet Systems extended their contract to implement a centralized automated platform for the Nu.Q Vet Cancer Test.

VolitionRX (VNRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VNRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-0.04 / -	-0.07	―	―	―
Aug 14, 2025	2025 (Q2)	-0.05 / -0.06	-0.085	29.41% (+0.03)	―
May 15, 2025	2025 (Q1)	- / -0.06	-0.1	40.00% (+0.04)	―
Mar 31, 2025	2024 (Q4)	-0.04 / -0.06	-0.1	40.00% (+0.04)	―
Nov 14, 2024	2024 (Q3)	-0.07 / -0.07	-0.11	36.36% (+0.04)	―
Aug 14, 2024	2024 (Q2)	-0.09 / -0.09	-0.14	39.29% (+0.06)	―
May 13, 2024	2024 (Q1)	-0.10 / -0.10	-0.15	33.33% (+0.05)	―
Mar 25, 2024	2023 (Q4)	-0.10 / -0.10	-0.13	23.08% (+0.03)	―
Nov 14, 2023	2023 (Q3)	-0.13 / -0.11	-0.14	21.43% (+0.03)	―
Aug 14, 2023	2023 (Q2)	-0.14 / -0.14	-0.14	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VNRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$0.64	$0.69	+7.81%
May 15, 2025	$0.45	$0.43	-4.44%
Mar 31, 2025	$0.57	$0.52	-8.77%
Nov 14, 2024	$0.72	$0.68	-5.56%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does VolitionRX (VNRX) report earnings?

VolitionRX (VNRX) is schdueled to report earning on Nov 13, 2025, After Close (Confirmed).

What is VolitionRX (VNRX) earnings time?

VolitionRX (VNRX) earnings time is at Nov 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VNRX EPS forecast?

VNRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing